Thu Sep 26 14:12:50 UTC 2024: ## Pacer Advisors Increases Stake in Sarepta Therapeutics Amid Positive Market Sentiment

**New York, NY (MarketBeat News) -** Pacer Advisors Inc. significantly increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, acquiring an additional 14,654 shares, representing a 4,259.9% surge. This move comes as several other institutional investors also show increased interest in the biotechnology company.

Pacer Advisors’ investment now totals 14,998 shares, valued at $2,370,000, signaling confidence in Sarepta’s future prospects. The company’s focus on developing treatments for rare diseases, particularly Duchenne Muscular Dystrophy, has attracted attention from several investors.

Several other institutional investors have also adjusted their positions in SRPT during recent quarters. Innealta Capital LLC and Mather Group LLC both acquired new positions in the second and first quarters, respectively. Riggs Asset Management Co. Inc. significantly increased its holdings by 125% in the first quarter. New Covenant Trust Company N.A. and Principal Securities Inc. also acquired new stakes during the first and fourth quarters, respectively.

The increased institutional interest comes alongside a wave of positive analyst recommendations. Robert W. Baird, Bank of America, William Blair, Needham & Company LLC, and BMO Capital Markets all raised their price targets on Sarepta Therapeutics. This positive sentiment has led to an average “Moderate Buy” rating with an average price target of $187.39, according to MarketBeat.com.

Sarepta Therapeutics recently reported strong earnings results, surpassing analysts’ expectations. The company’s revenue surged 38.9% year-over-year, fueled by the success of its Duchenne Muscular Dystrophy treatments.

While several insiders have sold shares, recent purchases by Director Michael Andrew Chambers also indicate optimism within the company.

Overall, the combination of positive market sentiment, increased institutional investment, and strong financial performance suggests that Sarepta Therapeutics is well-positioned for continued growth in the coming months.

Read More